The following data will be presented: The Impact of Treatment Gaps on Effectiveness of Transcranial Magnetic Stimulation in MDD Presented by: Sonder Behavioral Health & Wellness, Minnetonka, Minnesota Overview: This study will showcase feasibility, safety, and efficacy results using NeuroStar with a pragmatic accelerated TMS protocol without the need for neuroimaging. Presentation Date: June 14th at 4:00 PM BST Presenter: Dr. Kenneth Pages, Medical Director of TMS of South Tampa Overview: Dr. Pages will con ...

"We are thrilled to present this meaningful evidence at the Clinical TMS Society Annual Meeting and engage with TMS providers and researchers about recent advancements in our field," said Cory Anderson, Senior Vice President of Research & Development and Clinical Affairs. "Our extensive data and strong clinical presence establish NeuroStar as the leading TMS device, treating the highest number of patients and supporting providers in delivering exceptional patient care in clinical settings." When to Hold and ...

MALVERN, Pa., May 23, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced that the management team will present at the William Blair 44th Annual Growth Stock Conference on Thursday, June 6, 2024. The Company is scheduled to present at 10:00am Central Time the same day via webcast. Neuronetics, Inc. believes that ment ...

财务数据和关键指标变化 - 总收入为17.4亿美元,同比增长12% [51] - 美国NeuroStar系统收入为3.3亿美元,发货41台系统 [51] - 美国治疗会话收入为1.3亿美元,同比增长22% [51][52] - 毛利率为75.1%,同比提升180个基点 [54] - 经营费用为2亿美元,同比下降7% [55] - 净亏损为7.9亿美元,每股亏损0.27美元 [56] - EBITDA为负6.3亿美元,同比改善 [57][58] - 截至3月31日,现金及等价物为4.77亿美元 [59] 各条业务线数据和关键指标变化 - NeuroStar系统收入受到客户信贷获取困难和Change Healthcare网络安全事件的影响,发货量略低于预期 [11][12] - 治疗会话收入增长22%,主要受益于本地耗材收入增长超过32% [19] - 治疗会话收入增长受到一些客户保守现金支出的影响 [20] 各个市场数据和关键指标变化 - 无具体披露 公司战略和发展方向及行业竞争 - 持续推进Better Me Guarantee Provider计划,已有204家医疗机构参与,患者转诊和治疗效果显著提升 [21][22][23][24][25][26] - 继续推广NeuroStar University教育计划,参与医疗机构平均使用量提升58% [27][28][29] - 扩大营销合作计划,参与医疗机构的治疗量和使用量均有提升 [30][31][32] - 获得FDA批准将NeuroStar用于15-21岁青少年抑郁症患者,这一新适应症将使公司的总可服务人群增加约35% [33][34][35][36][40] - 公司将加大对青少年患者及其家长的教育和宣传力度,以提高认知度和使用率 [43][44][45] 管理层对经营环境和未来前景的评论 - 受到Change Healthcare网络安全事件的影响,一些医疗机构推迟了系统购买和现金收款,但预计随着事件的解决,业务将会恢复 [11][12][59] - 公司有信心在2024年第四季度实现现金流正转,并保持长期可持续增长 [64][65][66] 其他重要信息 - 公司董事会三位成员将不再参选连任 [67] 问答环节重要的提问和回答 问题1 **Ellie Jiang 提问** 为什么在青少年适应症批准和治疗会话收入强劲增长的情况下,公司仍保持全年收入指引不变? [70] **Jiazhen Zhao 回答** 由于Change Healthcare事件的不确定性影响,公司保持谨慎态度,尽管预计第二季度及以后会有反弹,但青少年适应症在2024年的贡献仍难以预测,2025年和2026年会有更大影响 [71][72] 问题2 **Yang Bai 提问** 第二季度收入指引略低于市场预期,是否主要由于资本设备销售的推迟? [79][80] **Jiazhen Zhao 回答** 是的,主要是由于客户获取信贷融资的周期延长,以及Change Healthcare事件导致的现金收款延迟,但公司预计第二季度至第四季度会有反弹 [81][82] 问题3 **Joyce Ju 提问** Better Me Guarantee计划和NeuroStar University的效果如何,是否会持续改善? [97][98][99][100][101][102][103] **Lei Chen 回答** Better Me Guarantee计划参与医疗机构的治疗量和效果持续提升,公司计划在今年6月底前将参与机构扩展至350-450家,效果将持续改善 [103][104]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission File Number: 001-38546 NEURONETICS, INC. (Exact name of registrant as specified in its charter) Delaware 33-10 ...

Exhibit 99.1 Neuronetics Reports Record First Quarter 2024 Financial and Operating Results MALVERN, PA., May 7, 2024 – Neuronetics, Inc. (NASDAQ: STIM) (the “Company” or “Neuronetics”) a commercial stage medical technology company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the best neurohealth therapies in the world, today announced its financial and operating results for the first quarter of 2024. First Quarter 2024 Highlights ● First quarter 20 ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission File Number: 001-38546 NEURONETICS, INC. (Exact name of registrant as specified in its charter) incorporation or or ...

Neuronetics, Inc. (NASDAQ:STIM) Q4 2023 Earnings Conference Call March 5, 2024 8:30 AM ET Company Participants Keith Sullivan - President, Chief Executive Officer Steve Furlong - Chief Financial Officer Mark Klausner - Investor Relations Conference Call Participants Adam Maeder - Piper Margaret Kaczor - William Blair William Plovanic - Canaccord Danny Stauder - Citizens JMP Operator Ladies and gentlemen, thank you for standing by. Welcome to the Neuronetics Report Fourth Quarter 2023 Financial and Operating ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission File Number: 001-38546 NEURONETICS, INC. (Exact name of registrant as specified in its charter) incorporat ...

Neuronetics, Inc. (NASDAQ:STIM) Q3 2023 Earnings Conference Call November 7, 2023 8:30 AM ET Company Participants Mark Klausner - ICR Westwicke Keith Sullivan - President and CEO Steve Furlong - CFO Conference Call Participants Margaret Kaczor - William Blair Adam Maeder - Piper Sandler Daniel Stauder - JMP Securities Operator Good day, and thank you for standing by. Welcome to the Neuronetics Third Quarter 2023 Conference Call. [Operator Instructions] Please be advised that today's conference call is being ...